Gain Therapeutics, Inc. — Q1 2021 Form 10-Q
Reporting period: Three months ended March 31, 2021. Gain Therapeutics is a preclinical-stage biotechnology company developing small-molecule therapies for diseases associated with protein misfolding, using its licensed SEE-Tx platform. It reported no product-sales revenue and had no approved products.
Key financial metrics
| Metric | Q1 2021 | Q1 2020 / comparison |
|---|---|---|
| Revenue | $5,269, primarily office sublease income | $6,673 |
| Research and development expense | $1.42 million | $417,259 |
| General and administrative expense | $1.05 million | $101,674 |
| Operating loss | $2.47 million | $512,260 |
| Net loss | $2.45 million; $0.50 per share | $584,268; $0.29 per share |
| Operating cash flow | $(2.81) million | $(753,000) |
| Cash, cash equivalents and restricted cash | $46.64 million | $945,000 at March 31, 2020 |
| Total assets / stockholders’ equity | $48.04 million / $44.46 million | At March 31, 2021 |
| Debt | $723,000 | Zero-interest Swiss-government-guaranteed loans |
Operating margin is not meaningful given negligible non-product revenue and the company’s development-stage operations. The filing reports an accumulated deficit of approximately $9.49 million at March 31, 2021. Cash and cash equivalents alone were $46.59 million. Financing cash flow of $41.99 million largely reflects the March IPO, net of certain offering-cost payments.
Material changes versus the prior comparable period
- Net loss increased to $2.45 million from $584,268, chiefly as research and development expense rose by about $1.00 million and G&A expense by about $949,000.
- R&D growth reflected expanded external preclinical services and personnel costs; G&A growth included added personnel and legal, accounting, professional-services and investor-relations costs.
- Cash increased substantially following the March 2021 IPO. The company issued approximately 4.18 million shares at $11 per share; the filing describes approximately $40.6 million in net proceeds after offering expenses.
- Preferred shares converted to common stock upon the IPO. Common shares outstanding were 11,876,460 at March 31, 2021.
Outlook, risks and unusual items
- Management expects losses and increased R&D spending for the foreseeable future. It planned to obtain further preclinical data and begin IND-enabling work for lead candidates in 2021. No clinical trials had begun, and candidates remained in early development.
- Management stated existing cash was expected to fund planned operations and capital expenditures for the foreseeable future; elsewhere, the risk discussion says cash was expected to support operations for at least 12 months. Funding needs depend on research progress, clinical development, regulatory work and other factors, and additional capital may be required.
- The company’s principal risks include preclinical or clinical failure and delay, regulatory uncertainty, difficulty enrolling patients with rare diseases, reliance on third parties and licensed technology, intellectual-property risk, competition, and potential future dilution or unfavorable financing terms. COVID-19 could disrupt research, vendors or access to capital; management said it had not significantly affected estimates to date.
- Disclosure controls and procedures were deemed ineffective at March 31, 2021 because of material weaknesses in the financial-close process, including insufficient accounting and supervisory resources and inadequate procedures for timely, accurate financial statements. Remediation was underway but not yet complete.
- The company reported no material legal proceedings. It also disclosed contractual commitments totaling approximately $2.86 million, including lease, loan and collaboration obligations.
Important facts for investors to verify
- Reconcile the IPO share and proceeds disclosures: the filing contains differing share counts in separate sections and reports proceeds at different stages of underwriting and offering-cost deductions.
- Confirm cash runway assumptions against planned preclinical and IND-enabling spending, and whether additional financing will be needed.
- Track candidate-specific preclinical results, IND-enabling progress and timing; no clinical-stage evidence was reported.
- Monitor remediation and testing of the disclosed material weaknesses, including whether disclosure controls become effective.
- Check share-count changes and potential dilution from outstanding options, warrants and future equity issuance.